This study aim is to assess impact of COVID-19 infection during pregnancy on outcome of pregnancy, and on developement of the child in early life.
All pregnant women will be tested for serology during each trimester of pregnancy and at
delivery, together with a nasal swab. Children born to women with positive sawb or serology
will be followed up for 3 years together with a control child born to negative mother.
In positive mothers, maternal antibodies at delivery will be characterized, placental
transfer will be assessed. Persistence of antibodies in children at the age of 1 month and
presence of antibodies in breast milk will be measured.
Occurence of premature birth, low birth weight, miscarriage, congenital malformations will be
compared in positive and negative mothers. Follow up of children over the first 3 years of
life will assess difference in susceptibility to infections and neurological developement in
both groups.
Other: no intervention
no intervention
Inclusion Criteria:
- For pregnant women, all women who deliver in the CHU St Pierre, with oral consent.
- For children follow up: children born to positive mothers and matched controls after
written consent
Exclusion Criteria:
- none
CHU SAINT Pierre
Brussels, Belgium
Tessa Goetghebuer, MD PhD, Principal Investigator
Centre Hospitalier Universitaire Saint Pierre